ArticleChirality2026
Chiral Tetraazacalix-Triazine Derivatives as Organocatalysts for Asymmetric Direct Aldol Reactions: Synthesis and Enantioselective Evaluation.
Article in Chirality, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel tetraazacalix derivatives were synthesized and evaluated for their catalytic performance in direct asymmetric aldol reactions carried out in organic solvents. Chiral functionalities were introduced onto the tetraazacalix[2]arene[2]triazine and tetraazacalix[4]arene[2]triazine framework via reactions with (S)-(+)-2-Phenylglycinol. The resulting tetraazacalix derivatives exhibited high catalytic efficiency in the aldol reactions between ketone and various aldehydes. The experimental results demonstrated that the structural moiety of the catalyst plays a decisive role in controlling the stereochemical configuration of the aldol products. Under the optimized conditions, the aldol adducts were obtained in excellent yields of up to 92% and enantioselectivities reaching 95%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.